Literature DB >> 22334387

The androgen receptor gene mutations database: 2012 update.

Bruce Gottlieb1, Lenore K Beitel, Abbesha Nadarajah, Miltiadis Paliouras, Mark Trifiro.   

Abstract

The current version of the androgen receptor gene (AR) mutations database is described. A major change to the database is that the nomenclature and numbering scheme now conforms to all Human Genome Variation Society norms. The total number of reported mutations has risen from 605 to 1,029 since 2004. The database now contains a number of mutations that are associated with prostate cancer (CaP) treatment regimens, while the number of AR mutations found in CaP tissues has more than doubled from 76 to 159. In addition, in a number of androgen insensitivity syndrome (AIS) and CaP cases, multiple mutations have been found within the same tissue samples. For the first time, we report on a disconnect within the AIS phenotype-genotype relationship among our own patient database, in that over 40% of our patients with a classic complete AIS or partial AIS phenotypes did not appear to have a mutation in their AR gene. The implications of this phenomenon on future locus-specific mutation database (LSDB) development are discussed, together with the concept that mutations can be associated with both loss- and gain-of-function, and the effect of multiple AR mutations within individuals. The database is available on the internet (http://androgendb.mcgill.ca), and a web-based LSDB with the variants using the Leiden Open Variation Database platform is available at http://www.lovd.nl/AR.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334387     DOI: 10.1002/humu.22046

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  145 in total

1.  Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.

Authors:  Milly J McAllister; Pamela McCall; Ashley Dickson; Mark A Underwood; Ditte Andersen; Elizabeth Holmes; Elke Markert; Hing Y Leung; Joanne Edwards
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-01       Impact factor: 5.554

2.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Authors:  Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

3.  Is there any clinical relevant difference between non mosaic Klinefelter Syndrome patients with or without Androgen Receptor variations?

Authors:  Umberto Valente; Cinzia Vinanzi; Savina Dipresa; Riccardo Selice; Massimo Menegazzo; Massimo Iafrate; Carlo Foresta; Andrea Garolla
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

Review 4.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

5.  Effects of androgen receptor mutation on testicular histopathology of patient having complete androgen insensitivity.

Authors:  Ihtisham Bukhari; Guangyuan Li; Liu Wang; Furhan Iqbal; Huan Zhang; Jiansheng Zhu; Hui Liu; Xiangdong Fang; Nasser M Al-Daghri; Howard J Cooke; Yuanwei Zhang; Xiaohua Jiang
Journal:  J Mol Histol       Date:  2017-03-15       Impact factor: 2.611

6.  Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.

Authors:  Krishna B Singh; Xinhua Ji; Shivendra V Singh
Journal:  Mol Cancer Ther       Date:  2018-07-20       Impact factor: 6.261

7.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Authors:  Ling Cai; Yi-Hsuan Tsai; Ping Wang; Jun Wang; Dongxu Li; Huitao Fan; Yilin Zhao; Rohan Bareja; Rui Lu; Elizabeth M Wilson; Andrea Sboner; Young E Whang; Deyou Zheng; Joel S Parker; H Shelton Earp; Gang Greg Wang
Journal:  Mol Cell       Date:  2018-09-27       Impact factor: 17.970

Review 8.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

9.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 10.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.